97 related articles for article (PubMed ID: 23380279)
1. Understanding the cell cycle in the pathophysiology of chordomas: a molecular look.
Kaloostian PE; Gokaslan ZL
World Neurosurg; 2014; 82(1-2):e135-7. PubMed ID: 23380279
[No Abstract] [Full Text] [Related]
2. A comparison of cell-cycle markers in skull base and sacral chordomas.
Yakkioui Y; Temel Y; Creytens D; Jahanshahi A; Fleischeuer R; Santegoeds RG; Van Overbeeke JJ
World Neurosurg; 2014; 82(1-2):e311-8. PubMed ID: 23416769
[TBL] [Abstract][Full Text] [Related]
3. Metastatic dedifferentiated chordoma with elevated beta-hCG: a case report.
Munshi HG; Merajver SD; Valdez R; Baker LH; Cooney KA
Am J Clin Oncol; 2002 Jun; 25(3):274-6. PubMed ID: 12040287
[TBL] [Abstract][Full Text] [Related]
4. Transcriptome comparison identifies potential biomarkers of spine and skull base chordomas.
Bell AH; DeMonte F; Raza SM; Rhines LD; Tatsui CE; Prieto VG; Fuller GN; Bell D
Virchows Arch; 2018 Mar; 472(3):489-497. PubMed ID: 28844110
[TBL] [Abstract][Full Text] [Related]
5. Chordomas of the Skull Base, Mobile Spine, and Sacrum: An Epidemiologic Investigation of Presentation, Treatment, and Survival.
Zuckerman SL; Bilsky MH; Laufer I
World Neurosurg; 2018 May; 113():e618-e627. PubMed ID: 29486315
[TBL] [Abstract][Full Text] [Related]
6. Analysis of immunohistochemical expression of p53 and the proliferation marker Ki-67 antigen in skull base chordomas: relationships between their expression and prognosis.
Sakai K; Hongo K; Tanaka Y; Nakayama J
Brain Tumor Pathol; 2007; 24(2):57-62. PubMed ID: 18095132
[TBL] [Abstract][Full Text] [Related]
7. [A clinicopathological and immunohistochemical study of 34 cases of chordoma].
Hu Y; Gao Y; Zhang X
Zhonghua Bing Li Xue Za Zhi; 1996 Jun; 25(3):142-4. PubMed ID: 9275666
[TBL] [Abstract][Full Text] [Related]
8. Disease outcomes for skull base and spinal chordomas: a single center experience.
Ahmed R; Sheybani A; Menezes AH; Buatti JM; Hitchon PW
Clin Neurol Neurosurg; 2015 Mar; 130():67-73. PubMed ID: 25590662
[TBL] [Abstract][Full Text] [Related]
9. Chordoma of the skull base: predictors of tumor recurrence.
Pallini R; Maira G; Pierconti F; Falchetti ML; Alvino E; Cimino-Reale G; Fernandez E; D'Ambrosio E; Larocca LM
J Neurosurg; 2003 Apr; 98(4):812-22. PubMed ID: 12691407
[TBL] [Abstract][Full Text] [Related]
10. Chordoma: Immunohistochemical Analysis of Brachury.
Sun HI; Guduk M; Gucyetmez B; Yapicier O; Pamir MN
Turk Neurosurg; 2018; 28(2):174-178. PubMed ID: 28094431
[TBL] [Abstract][Full Text] [Related]
11. Skull base chordoma and chondrosarcoma: influence of clinical and demographic factors on prognosis: a SEER analysis.
Bohman LE; Koch M; Bailey RL; Alonso-Basanta M; Lee JY
World Neurosurg; 2014 Nov; 82(5):806-14. PubMed ID: 25009165
[TBL] [Abstract][Full Text] [Related]
12. [Chordoma].
George B; Bresson D; Bouazza S; Froelich S; Mandonnet E; Hamdi S; Orabi M; Polivka M; Cazorla A; Adle-Biassette H; Guichard JP; Duet M; Gayat E; Vallée F; Canova CH; Riet F; Bolle S; Calugaru V; Dendale R; Mazeron JJ; Feuvret L; Boissier E; Vignot S; Puget S; Sainte-Rose C; Beccaria K
Neurochirurgie; 2014 Jun; 60(3):63-140. PubMed ID: 24856008
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of the BMP4/SMAD signaling pathway in skull base chordomas is associated with poor prognosis.
Feng Y; Zhang Q; Wang Z; Yan B; Wei W; Li P
Int J Clin Exp Pathol; 2015; 8(7):8268-75. PubMed ID: 26339396
[TBL] [Abstract][Full Text] [Related]
14. Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmocological Inhibitors of the CDK4/6 Cell-Cycle Pathway.
von Witzleben A; Goerttler LT; Marienfeld R; Barth H; Lechel A; Mellert K; Böhm M; Kornmann M; Mayer-Steinacker R; von Baer A; Schultheiss M; Flanagan AM; Möller P; Brüderlein S; Barth TF
Cancer Res; 2015 Sep; 75(18):3823-31. PubMed ID: 26183925
[TBL] [Abstract][Full Text] [Related]
15. Base of skull chordomas in children and adolescents: a clinicopathologic study of 73 cases.
Hoch BL; Nielsen GP; Liebsch NJ; Rosenberg AE
Am J Surg Pathol; 2006 Jul; 30(7):811-8. PubMed ID: 16819322
[TBL] [Abstract][Full Text] [Related]
16. Expression of ezrin, MMP-9, and COX-2 in 50 chordoma specimens: a clinical and immunohistochemical analysis.
Froehlich EV; Scheipl S; Lazàry A; Varga PP; Schmid C; Stammberger H; Beham A; Bodo K; Schroettner H; Quehenberger F; Windhager R; Liegl B; Leithner A
Spine (Phila Pa 1976); 2012 Jun; 37(13):E757-67. PubMed ID: 22228328
[TBL] [Abstract][Full Text] [Related]
17. The Role of EGFR, Hepatocyte Growth Factor Receptor (c-Met), c-ErbB2 (HER2-neu) and Clinicopathological Parameters in the Pathogenesis and Prognosis of Chordoma.
Tosuner Z; Bozkurt SU; Kiliç T; Yilmaz B
Turk Patoloji Derg; 2017; 33(2):112-120. PubMed ID: 28272674
[TBL] [Abstract][Full Text] [Related]
18. T gene isoform expression pattern is significantly different between chordomas and notochords.
Wang K; Hu Q; Wang L; Chen W; Tian K; Cao C; Wu Z; Jia G; Zhang L; Zeng C; Zhang J
Biochem Biophys Res Commun; 2015 Nov; 467(2):261-7. PubMed ID: 26435504
[TBL] [Abstract][Full Text] [Related]
19. Clinical characteristics, immunohistochemistry, and outcomes of 77 patients with skull base chordomas.
Ouyang T; Zhang N; Zhang Y; Jiao J; Ren J; Huang T; Chen J
World Neurosurg; 2014; 81(5-6):790-7. PubMed ID: 23298670
[TBL] [Abstract][Full Text] [Related]
20. Brachyury: A sensitive marker, but not a prognostic factor, for skull base chordomas.
Wang K; Tian K; Wang L; Wu Z; Ren C; Hao S; Feng J; Li J; Wan H; Jia G; Zhang L; Zhang J
Mol Med Rep; 2015 Sep; 12(3):4298-4304. PubMed ID: 26099340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
